UPDATE 3-Lilly beats forecasts, vows to remain independent
July 24, 2014 at 12:12 PM EDT
July 24 (Reuters) - Eli Lilly and Co's quarterly revenue plunged due to generic competition for its Cymbalta depression drug and its Evista osteoporosis treatment, but cost controls helped earnings beat forecasts.